The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Antipsychotic Drugs Market Progress Between 2026 And 2030?
The antipsychotic drugs market size has demonstrated significant expansion in recent years. It is anticipated to increase from $21.25 billion in 2025 to $23.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. This historical growth can be ascribed to the emergence of first-generation antipsychotics, heightened awareness of mental health disorders, the enlargement of hospital and clinical infrastructure, the escalating prevalence of schizophrenia and bipolar disorder, and augmented r&d investments in neuropsychiatric drugs.
The antipsychotic drugs market is anticipated to show robust expansion over the coming years, reaching $33.26 billion by 2030, with a compound annual growth rate (CAGR) of 9.4%. This expected growth during the forecast period stems from advancements in atypical and partial dopamine agonists, the adoption of precision medicine approaches, the integration of AI in mental health diagnostics, the expansion of online pharmacy distribution channels, and a heightened focus on long-acting injectable formulations. Prominent trends within this forecast period include personalized antipsychotic therapy, an increasing geriatric population, the rising prevalence of schizophrenia and bipolar disorder, the widespread use of telepsychiatry and digital mental health platforms, and the continued development of long-acting injectable antipsychotics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp
Which Primary Drivers Are Impacting The Antipsychotic Drugs Market Growth?
The rising occurrence of mental disorders is projected to fuel the expansion of the antipsychotic drug market in the future. These conditions, frequently termed mental illnesses, are health issues that affect an individual’s thoughts, actions, feelings, and overall mental well-being. Various factors, including stress levels, societal pressures, genetic predisposition, biochemical imbalance, neurodevelopmental issues, and physical health conditions, can influence instances of mental disorders. Antipsychotic medications manage mental disorders by modifying the activity of neurotransmitters, chiefly dopamine and serotonin, thereby diminishing psychotic symptoms, stabilizing mood, and enhancing cognitive and emotional function. For example, in November 2023, data from a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based government public health agency, indicated that roughly 6% of adults aged 18 or older, totaling 15.4 million people, reported experiencing serious mental illness (SMI). Additionally, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, forecast that the number of people living with dementia in Australia is anticipated to more than double from approximately 411,100 in 2023 to 849,300 by 2058. This surge is expected to impact around 315,500 men and 533,800 women. Consequently, the increasing prevalence of mental disorders is propelling the antipsychotic drug market.
How Is The Antipsychotic Drugs Market Organized By Segment Classification?
The antipsychotic drugs market covered in this report is segmented –
1) By Therapeutic Class: First Generation, Second Generation, Third Generation
2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies
Subsegments:
1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines
2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone
3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine
What Trends Are Transforming The Antipsychotic Drugs Market?
Key companies in the antipsychotic drug market are focusing on developing advanced medical products, such as subcutaneous atypical antipsychotic injections, to provide improved patient compliance and enhanced efficacy compared to traditional oral medications. Subcutaneous atypical antipsychotic injections are psychiatric medications delivered under the skin to treat mental illnesses, maintain stable blood levels, and improve symptom control. For example, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, along with MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, introduced U.S. Food and Drug Administration (FDA)-approved UZEDY. This product is an extended-release injectable risperidone formulation, designed as a long-acting subcutaneous injection, offering flexible dosing intervals of one or two months. UZEDY employs MedinCell’s proprietary SteadyTeq technology, which ensures a steady release of the medication, reaching therapeutic levels within 6–24 hours of administration. Clinical trials showed that UZEDY led to up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. It aims to address adherence challenges frequently associated with oral antipsychotics, which often contribute to relapse.
Who Are The Industry Participants Involved In The Antipsychotic Drugs Market?
Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc
Get The Full Antipsychotic Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report
Which Region Dominates The Antipsychotic Drugs Market By Market Share?
North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Antipsychotic Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report
Browse Through More Reports Similar to the Global Antipsychotic Drugs Market 2026, By The Business Research Company
Antipsychotic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report
Anticholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Epilepsy Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model